Previous 10 | Next 10 |
2023-08-30 13:42:43 ET Summary Tweedy, Browne's 13F portfolio value increased by 4% to $1.91B, with 46 holdings. Berkshire Hathaway is the largest position at 22% of the portfolio, followed by Alphabet, Johnson & Johnson, Coca-Cola FEMSA, and Ionis Pharma. New stakes inclu...
2023-08-09 16:25:26 ET Ionis Pharmaceuticals, Inc. (IONS) Q2 2023 Earnings Conference Call August 9, 2023 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - CEO Richard Geary - Chief Development Officer Beth Hougen - CFO Onaiza Cadoret - ...
2023-08-09 07:04:09 ET Ionis Pharmaceuticals press release ( NASDAQ: IONS ): Q2 GAAP EPS of -$0.60 beats by $0.28 . Revenue of $188M (+40.3% Y/Y) beats by $46.08M . Cash and short-term investments of $2.4 billion as of June 30, 2023 enables continued investment...
Ionis reports second quarter 2023 financial results PR Newswire Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks; December 22, 2023 PDUFA date Completed enrollment in donidalorsen OASIS-HAE study and eplontersen C...
2023-08-08 12:44:53 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$0.70 (+5.4% Y/Y) and the consensus Revenue Estimate is $141.92M (+5.9% Y/Y). Over th...
2023-08-03 08:28:46 ET More on Ionis, Novartis, etc. Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Ionis: Potential Advancement Into HAE Space Makes This A Must Watch Novartis Buys Chinook: M&...
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease PR Newswire Builds on existing collaboration with Novartis for pelacarsen, which is currently being evaluated in a Phase 3 cardiovascular outcome study with data expected...
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy PR Newswire CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled Eplontersen is currently ...
2023-07-28 08:05:33 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) announced Friday that AstraZeneca ( NASDAQ: AZN ) has agreed to broaden its agreement for the company’s investigational therapy eplontersen to include countries in Latin America. Eplontersen, discovered...
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America PR Newswire Companies jointly developing and commercializing eplontersen in the U.S. AstraZeneca adds Latin America as part of its exclusive rights for rest of wor...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...